Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Large Drop in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 114,388 shares, a drop of 71.6% from the August 31st total of 403,209 shares. Based on an average trading volume of 95,127 shares, the short-interest ratio is currently 1.2 days. Approximately 5.0% of the company’s shares are sold short.

Kairos Pharma Stock Performance

Shares of KAPA stock opened at $1.72 on Friday. The firm has a market capitalization of $5.83 million, a price-to-earnings ratio of -0.88 and a beta of 1.48. Kairos Pharma has a one year low of $1.51 and a one year high of $9.59. The company has a 50 day moving average price of $2.01 and a 200 day moving average price of $3.02.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Kairos Pharma will post -2.59 EPS for the current fiscal year.

Kairos Pharma Company Profile

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on immuno-oncology, with an emphasis on addressing mechanisms that can cause tumors to resist existing treatments.

Kairos Pharma’s lead program, KPA-1102, is an investigational antibody designed to inhibit leukemia inhibitory factor (LIF), a signaling protein associated with tumor growth and immune suppression. The company is evaluating the potential use of this approach in combination with other cancer therapies, including immune checkpoint inhibitors.

The company is based in the United States and is focused primarily on advancing its drug candidates through clinical development and regulatory processes.